However, a lot of subscribers are thinking about the move.
Only 6% of all online adults have cut the cord in favor of Net-delivered video, a Forrester Research report from February found in a survey of more than 4,600. And since nearly all adults are online (91%) that covers most of the subscriber market.
But Forrester did find that the amount of cord cutters rose to 10% when it narrowed results to younger adults ages 18-24. And there's another 14% of the 18-24-year-olds who are thinking seriously about dropping pay TV for Net TV. Among all online adults, 9% are considering cutting the cord.
A similar finding comes from Digitalsmiths, a TV tech company owned by TiVo. Its report, released in March and surveying more than 3,140 adults, found that 10.8% of respondents could potentially leave their current pay TV provider in the next six months. Most said they plan to change providers, while others plan to cut their pay TV service altogether or switch to a third-party app.
Hot China Companies To Watch For 2016: Systemax Inc.(SYX)
Systemax Inc. operates as a direct marketer of brand name and private label products. The company operates in two segments, Technology Products and Industrial Products. The Technology Products segment sells computers, computer supplies, and consumer electronics in North America and Europe. This segment offers individual technology products in categories, including computers; computer parts; television and video; audio; cameras and surveillance; car and GPS; cell phones; software; video games and toys; home and office; and other products. The Industrial Products segment sells various industrial products and supplies in North America. This segment provides products in categories, such as material handling; storage and shelving; workbench and shop desks; packaging and supplying; furniture and office; foodservice and appliances; janitorial and maintenance; tools and instruments; fasteners and hardware; motors and power transmission; HVAC/R and fans; electrical and bulbs; plumb ing supplies; and safety and medical items. The company offers its products through its relationship marketers, catalog mailings, and Internet Websites. It serves individual consumers; and business customers comprising for-profit businesses, educational organizations, and government entities. Its portfolio of catalogs comprises various brand names, such as TigerDirect.com, Global Computer Supplies, TigerDirect.ca, Misco, Global Industrial, Nexel, and Inmac WStore. As of December 31, 2011, the company operated 42 retail stores in North America; and 7 distribution centers in Europe. Systemax Inc. was founded in 1949 and is headquartered in Port Washington, New York.
Advisors' Opinion:- [By Rich Duprey]
Loyalty and marketing specialist Alliance Data Systems (NYSE: ADS ) grabbed a tiger by the tail with a multiyear agreement to�provide private label credit card services�to�Systemax (NYSE: SYX ) subsidiary TigerDirect.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Systemax (NYSE: SYX ) , whose recent revenue and earnings are plotted below.
Top 10 Integrated Utility Stocks To Buy Right Now: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.
The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson�� Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.
Advisors' Opinion:- [By Michael Robinson]
CSD is also tapping into the biotech boom. Another firm that it holds, and we like, is Prothena Corporation PLC (PRTA), a clinical-stage biotechnology firm focused on Parkinson's disease and other neurodegenerative disorders.
- [By Lauren Pollock]
Roche Holding AG(ROG.VX) has entered a pact with Prothena Corp.(PRTA) PLC to develop and commercialize a treatment the clinical-stage biotechnology firm is developing for Parkinson’s disease. In after-hours trading, Prothena’s stock rose 8.6% to $29.75 premarket.
Top 10 Integrated Utility Stocks To Buy Right Now: Saes Getters SpA (SG&A)
SAES Getters SpA is an Italy-based company primarily engaged in the production of getters and metal dispensers. The Company structures its business into three main units: Industrial Applications, which includes getters and metal dispensers used in light sources and electron vacuum devices, getters for microelectronic and micromechanical systems, pumps for vacuum systems, getters for solar collectors, products for thermal insulation, and gas purifier systems; Shape Memory Alloys, which includes shape memory alloy semi-finished products, components and devices for medical and industrial applications, and Information Displays, which includes getters and metal dispensers for liquid crystal displays, and barium getters for cathode ray tubes. Additionally, through the Business Development Unit, the Company produces dryers and getters for organic light-emitting diode (OLED), sealants for solar panels and energy storage getter devices. Advisors' Opinion:- [By Jason Rivera]
To help facilitate this destruction of value has been that Koss has bought back a lot of its shares as the company has been overvalued. The below quote is from its most recent annual report.
In April of 1995, the Board of Directors approved a stock repurchase program authorizing the Company to purchase from time to time up to $2,000,000 of its common stock for its own account. Subsequently, the Board of Directors periodically has approved increases in the stock repurchase program. As of June 30, 2012, the most recently approved increase was for additional purchases of $2,000,000, which occurred in October of 2006, for an aggregate maximum of $45,500,000, of which $43,360,247 had been expended through June 30, 2012 . No purchases were made during the year ended June 30, 2012. The Company intends to effect all stock purchases either on the open market or through privately negotiated transactions and intends to finance all stock purchases through its own cash flow or by borrowing for such purchases.As you can see from this page, most of KOSS' margins have dropped substantially since 2007. Especially of note is its operating margin, ROE and ROIC. Book value per share, cash flow per share, revenue and working capital have all dropped substantially as well. Normally when I have evaluated companies' cost of goods sold rising is what has caused the above metrics to drop, but that has stayed relatively stable over the years at KOSS. The culprit in this case is selling, general and administrative (SG&A) related expenses expressed below as a percentage of its sales. The following numbers were taken from Morningstar: - [By GURUFOCUS]
For investors, Qualcomm understand the benefits of cloud services. It seems there are numerous questions unresolved. Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, initiating overhauls of its R&D and selling, general and administrative (SG&A) segments for Pharma. A company willing to build their capabilities, and open to a new view of value will likely achieve better outcomes. Delivering support, personalization, scalability, speed and flexibility are attractive areas for growth.
Top 10 Integrated Utility Stocks To Buy Right Now: AmBase Corp (ABCP)
AmBase Corporation (AmBase), incorporated in 1975, is a holding company. The Company, through its wholly owned subsidiary, owns one commercial office building in Greenwich, Connecticut, which is managed and operated by the Company.
The building is approximately 14,500 square feet, with approximately 3,500 square feet utilized by the Company for its executive offices, and the remaining space was unoccupied and available for lease as of December 31, 2011. The Company has also purchased convertible preferred and common stock in AMDG, Inc. (AMDG).
Advisors' Opinion:- [By Lisa Levin]
Property Management: This industry jumped 6.35% by 11:30 am. The top performer in this industry was AmBase (OTC: ABCP), which rose 2.4%. AmBase shares have gained 2.52% over the past 52 weeks, while the S&P 500 index has surged 14.46% in the same period.
Top 10 Integrated Utility Stocks To Buy Right Now: 1st Constitution Bancorp(NJ)
1st Constitution Bancorp operates as a bank holding company for 1st Constitution Bank that provides community banking services to corporations, individuals, partnerships, and other community organizations in the central and northeastern New Jersey area. It offers various deposit products, including noninterest bearing demand deposits, interest bearing demand deposits, savings deposits, and time deposits, as well as certificates of deposit, and money market and NOW accounts. The company also provides a range of loan products comprising commercial loans for working capital, business expansion, and the purchase of equipment and machinery; construction loans to real estate developers for the acquisition, development and construction of residential subdivisions; residential consumer loans; term loans; lines of credit; loans secured by equipment and receivables; second mortgage home improvement loans; home equity lines of credit; and non-residential consumer loans for automobile s, recreation vehicles, and boats, as well as secured and unsecured personal loans, and deposit account secured loans. It provides its services through a network of 14 branches. The company was founded in 1989 and is based in Cranbury, New Jersey.
Advisors' Opinion:- [By Monica Gerson]
Nidec (NYSE: NJ) shares climbed 2.75% to $20.17. The volume of Nidec shares traded was 506% higher than normal. Nidec's trailing-twelve-month revenue is $9.42 billion.
- [By Mark Skousen]
And that brings me to Nidec (NJ). Based in Kyoto, Japan, Nidec manufactures small- to mid-size motors, fan motors, and pivot assemblies used in dozens of IT products, as well as home appliances, automobiles, office equipment, and industrial machinery.
Top 10 Integrated Utility Stocks To Buy Right Now: Enzon Pharmaceuticals Inc. (ENZN)
Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs. The company?s drug-development programs utilize two platforms-Customized PEGylation Linker Technology and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. It currently holds four compounds in clinical development and multiple novel LNA targets in preclinical research. The company?s development product pipeline consists of PEG-SN38 compound that utilizes Customized Linker Technology, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer, as well as a Phase I trial for pediatric patients with cancer; and the Hypoxia-Inducible Factor-1 alpha antagonist in Phase I studies for the treatment of solid tumors and lymphoma. Its product line also comprises Survivin antagonist in Phase I study in pediatric patients with recurrent acute lymphoblas tic leukemia; Androgen Receptor antagonist, a validated target for the treatment of prostate cancer that is in a Phase I study in patients with castration-resistant prostate cancer; and rights to five compounds, including AR, HER3, beta-catenin, PI3KCA, and Gli2. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Piscataway, New Jersey.
Advisors' Opinion:- [By Lisa Levin]
Enzon Pharmaceuticals (NASDAQ: ENZN) shares fell 2.57% to touch a new 52-week low of $1.11. Enzon Pharmaceuticals shares have dropped 75.85% over the past 52 weeks, while the S&P 500 index has gained 24.92% in the same period.
- [By Equities Lab]
The stocks that currently pass the stock screen in order of market cap are Frontier Communications Corp , Crown Media Holdings (CRWN), Vonage Holding (VG), MCG Capital Corp (MCGC), 1-800-FLOWERS.COM (FLWS), MTR Gaming Corporation (MNTG), Alaska Communications (ALSK), and Enzon Pharmaceuticals (ENZN).
- [By Bryan Murphy]
With just a quick glance at the company's recent news (or lack thereof), Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) doesn't look like anything all that special... or even trade-worthy. It only takes a brief look at the chart of ENZN, however, to conclude this stock - lack of new or not - has just become something trade-worthy, because the rest of the market has clearly started to fall back in love with it; there's no telling at what price the love affair could end.
- [By Monica Wolfe]
Over the past week Seth Klarman (Trades, Portfolio) of The Baupost Group made one real time reduction; the guru reduced his holdings in Enzon Pharmaceutical (ENZN).� The guru cut his holdings in the company -43.6% by selling 3,353,595 shares of the company�� stock.� He sold these shares at an average price of $1.15 per share; the shares are still currently trading at around the same price.
Top 10 Integrated Utility Stocks To Buy Right Now: iShares Dow Jones US Energy Sector Fund (IYE)
iShares Dow Jones U.S. Energy Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Oil & Gas Index (the Index). The Index measures the performance of the oil and gas sector of the United States equity market. The Index includes companies in industry groups, such as oil and gas producers, and oil equipment, services and distribution. The Index is a subset of the Dow Jones U.S. Total Market Index and is capitalization weighted. The Index is reconstituted quarterly.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Aaron Levitt]
Fellow InvestorPlace contributor Lawrence Meyers recently recommended the Energy SPDR (XLE) as good ETF to hold for life. I like the pick and you could certainly do worse, but my personal favorite way�to play WTI crude would be the iShares U.S. Energy ETF (IYE).
- [By Louis Navellier]
The ishares Dow Jones U.S. Energy Sector Fund (IYE) tracks the performance of 99 major energy stocks in the U.S. IYE is actually up 20% for the year, but it has been trending downward over the past month. Meanwhile, the ishares S&P Global Energy Sector Fund (IXC) is up just 10% so far for the year. This fund, which also contains 99 holdings from all over the world, provides perhaps the best view of how the energy sector is faring on the global level. It has also fallen in the past month.
No comments:
Post a Comment